1.0Gene Therapy Center/genetherapyBetsy Clarke/genetherapy/author/bclarke/rich600338<blockquote class="wp-embedded-content" data-secret="qS6y7n8E2m"><a href="/genetherapy/research-laboratories/mccown-lab-1/thomas-mccown/">Thomas McCown</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="/genetherapy/research-laboratories/mccown-lab-1/thomas-mccown/embed/#?secret=qS6y7n8E2m" width="600" height="338" title="“Thomas McCown” — Gene Therapy Center" data-secret="qS6y7n8E2m" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript"> /* <![CDATA[ */ /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); /* ]]> */ </script> Research Interests Dr. McCown’s overall research entails the development of viral vector gene therapy for the treatment of neurological disorders. With a primary focus upon intractable temporal lobe epilepsy, Dr. McCown continues to refine the use of site directed gene therapy, as well as advance the potential of an intravenous AAV gene therapy. In addition, … Read more